Skip to search formSkip to main contentSkip to account menu

Vemurafenib

Known as: 1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3- yl)carbonyl)-2,4-difluorophenyl)-, 1-propanesulfonamide, n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-, N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4- difluorophenyl)propane-1-sulfonamide 
An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib… 
National Institutes of Health

Related topics

Related topics

13 relations

Broader (4)

Antineoplastic AgentsEnzyme InhibitorsIndolesSulfonamides
BRAF protein, humanInhibition of Cell ProliferationNCIt Antineoplastic Agent TerminologyPositive Regulation of Apoptosis

Narrower (3)

PLX4032RG7204Zelboraf

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
BRAFV600E-mutant cancers display a variety of networks by SWIM analysis: prediction of vemurafenib clinical response
PurposeSeveral studies have shown that different tumour types sharing a driver gene mutation do not respond uniformly to the same… 
2015
2015
Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms.
Variable clinical responses, tumor heterogeneity, and drug resistance reduce long-term survival outcomes for metastatic melanoma… 
Highly Cited
2014
Highly Cited
2014
Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic…
2511 Background: D, T, and Ipi are each indicated for treatment of patients (pts) with MM (D+T in BRAF V600 mutation–positive MM… 
2014
2014
COX‐2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors
Highly Cited
2014
Highly Cited
2014
BRAF inhibitors in cancer therapy.
2014
2014
Molecular Pathways Molecular Pathways : Response and Resistance to BRAF and MEK Inhibitors in BRAFV 600 E Tumors
The RAS–RAF–MEK (MAP–ERK kinase)–ERK (extracellular signal–regulated kinase) pathway plays a central role in driving… 
2014
2014
Case of vemurafenib‐induced Sweet's syndrome
Vemurafenib is a targeted therapy that has become standard treatment for patients with advanced melanoma with a V600E BRAF… 
Review
2013
Review
2013
Advances in therapy for melanoma brain metastases.
Review
2013
Review
2013
High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases
A retrospective review was performed on patients with stable melanoma brain metastases treated with HD IL-2 therapy (720,000 IU… 
2012
2012
Vemurafenib-induced neutrophilic panniculitis.
Vemurafenib is a targeted therapy, used in patients with metastatic cutaneous melanoma who carry the BRAF V600E mutation, with a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)